<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NORTHERA- droxidopaÂ capsuleÂ </strong><br>Lundbeck LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use NORTHERA safely and effectively. See full prescribing information for NORTHERA.<br><br>NORTHERAâ„¢ (droxidopa) capsules, for oral use<br>Initial U.S. Approval: 2014</span></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold"><span class="Bold">WARNING: SUPINE <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span><br></span></span><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span>
</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">Â </span></span></h1>
<p class="Highlighta"><span class="Bold">Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses.Â  Elevating the head of the bed lessens the risk of supine </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and blood pressure should be measured in this position.Â  If supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA <span class="Italics">[see Warnings and </span></span><span class="Bold"><span class="Italics">Precautions (<a href="#LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56">5.1</a>)].</span></span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold"><span class="Bold">WARNING: SUPINE <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span><br></span></span><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span>
</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">Â </span></span></h1>
<p class="Highlighta"><span class="Bold">Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses.Â  Elevating the head of the bed lessens the risk of supine </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and blood pressure should be measured in this position.Â  If supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA <span class="Italics">[see Warnings and </span></span><span class="Bold"><span class="Italics">Precautions (<a href="#LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56">5.1</a>)].</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NORTHERA is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">orthostatic dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, or the â€œfeeling that you are about to black outâ€? in adult patients with symptomatic neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> caused by primary autonomic failure (Parkinson's disease, multiple system <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>. Effectiveness beyond 2 weeks of treatment has not been demonstrated.Â  The continued effectiveness of NORTHERA should be assessed periodicallyÂ (<a href="#LINK_08e882d6-f70c-4279-9d66-5b90630e62ef">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>Starting dose is 100 mg three times during the day (<a href="#LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf">2.1</a>) 
</li>
<li>Titrate by 100 mg three times daily, up to a maximum dose of 600 mg three times dailyÂ (<a href="#LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf">2.1</a>) 
</li>
<li>Take consistently with or without food (<a href="#LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf">2.1</a>) 
</li>
<li>To reduce the potential for supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, elevate the head of the bed and give the last dose at least 3 hours prior to bedtime (<a href="#LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf">2.1</a>) 
</li>
<li>TakeÂ NORTHERA capsule whole<span class="Bold">Â </span>(<a href="#LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf">2.1</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li>100 mg, 200 mg, and 300 mg capsules (<a href="#LINK_b7e8ffed-3655-4f27-9e97-b56b0ff05651">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk"><li>None (<a href="#LINK_dc1acd69-4e56-4ce6-bcb2-c02384f0280e">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>NORTHERA can cause supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and may increase cardiovascular risk if supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is not well-managed (<a href="#LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56">5.1</a>).
</li>
<li><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (<a href="#LINK_6df41a12-20e4-4b28-b386-b5000bb32a6e">5.2</a>) 
</li>
<li>May exacerbate symptoms in patients with existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (<a href="#LINK_1685d806-6683-4fde-9518-fe5dd64aecbe">5.3</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> (<a href="#LINK_2779cd53-d849-46b6-abfa-1a5e48bda3a8">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (greater than 5%)Â (<a href="#LINK_e270b662-7849-498e-8175-a1a045f7ee1a">6.1</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch. Â </span></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li>Use of DOPA decarboxylase inhibitors may require dose adjustments for NORTHERAÂ (<a href="#LINK_6fcf6183-6379-4a4b-b1c7-9bba776cdaeb">7.2</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Italics">Nursing Mothers</span>:Â Choose nursing or NORTHERA (<a href="#LINK_9cd96db8-bd87-4944-b9da-f35534352f52">8.3</a>) 
</li>
<li>
<span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: Dosing recommendations cannot be provided for patients with GFR less than 30 mL/min (<a href="#LINK_e55a9213-2aa2-4b7e-aa79-ca3e8d09b210">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: SUPINE <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs that Increase Blood Pressure</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Parkinson's Medications</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">
10 OVERDOSAGE
</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Symptoms</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Treatment</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">
12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">
13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Studies in Neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_446f73e6-0c34-4640-9bbe-8a77a7c4fe2c"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: SUPINE <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span></span></h1>
<p class="First"><span class="Bold">Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses.Â  Elevating the head of the bed lessens the risk of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and blood pressure should be measured in this position.Â  If supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA</span>Â <span class="Bold"><span class="Italics">[see Warnings and Precautions (<a href="#LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56">5.1</a>)].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_08e882d6-f70c-4279-9d66-5b90630e62ef"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">NORTHERA is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">orthostatic dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, or the â€œfeeling that you are about to black outâ€? in adult patients with symptomatic neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and pure autonomic failure], dopamine beta-hydroxylase deficiency, and non-diabetic <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>. Effectiveness beyond 2 weeks of treatment has not been established.Â  The continued effectiveness of NORTHERA should be assessed periodically.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_03700bcf-3188-4486-8003-b1dc8c421f39"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_781898d3-0bc3-4cb7-9a7c-1782e5957ddf"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended starting dose of NORTHERA is 100 mg, taken orally three times daily: upon arising in the morning, at midday, and in the late afternoon at least 3 hours prior to bedtime (to reduce the potential for supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during sleep). Administer NORTHERA consistently, either with food or without food. Take NORTHERA capsule whole. Titrate to symptomatic response, in increments of 100 mg three times daily every 24 to 48 hours up to a maximum dose of 600 mg three times daily (i.e., a maximum total daily dose of 1,800 mg).</p>
<p>Monitor supine blood pressure prior to initiating NORTHERA and after increasing the dose. </p>
<p>Patients who miss a dose of NORTHERA should take their next scheduled dose. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_b7e8ffed-3655-4f27-9e97-b56b0ff05651"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NORTHERA capsules are available in 100 mg, 200 mg, and 300 mg strengths as specified below.</p>
<ul class="Disk">
<li>100 mg:Â Hard gelatin capsules with â€œNortheraâ€? on the white body and â€œ100â€? on the light blue cap 
</li>
<li>200 mg:Â Hard gelatin capsules with â€œNortheraâ€? on the white body and â€œ200â€? on the light yellow cap 
</li>
<li>300 mg:Â Hard gelatin capsules with â€œNortheraâ€? on the white body and â€œ300â€? on the light green cap </li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_dc1acd69-4e56-4ce6-bcb2-c02384f0280e"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_c8fca3d8-3d43-4f75-acac-15017be52a33"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NORTHERA therapy may cause or exacerbate supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients with NOH. Patients should be advised to elevate the head of the bed when resting or sleeping. Monitor blood pressure, both in the supine position and in the recommended head-elevated sleeping position. Reduce or discontinue NORTHERA if supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> persists. If supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is not well-managed, NORTHERA may increase the risk of cardiovascular events. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6df41a12-20e4-4b28-b386-b5000bb32a6e"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></h2>
<p class="First">Post-marketing cases of a symptom complex resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS) have been reported with NORTHERA use during post-marketing surveillance in Japan.Â  Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics.</p>
<p>NMS is an uncommon but life-threatening syndrome characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, involuntary movements, altered consciousness, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>.Â  The early diagnosis of this condition is important for the appropriate management of these patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1685d806-6683-4fde-9518-fe5dd64aecbe"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">NORTHERA may exacerbate existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.Â  Careful consideration should be given to this potential risk prior to initiating therapy in patients with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2779cd53-d849-46b6-abfa-1a5e48bda3a8"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_820022a8-5304-489f-bec6-8dfe8db57aab"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:</p>
<ul class="Disk">
<li>Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_d94e6e5f-6f69-4ed3-aaf1-3e7ed392ab56">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_6df41a12-20e4-4b28-b386-b5000bb32a6e">5.2</a>)]</span>
</li>
<li>May exacerbate existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_1685d806-6683-4fde-9518-fe5dd64aecbe">5.3</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e270b662-7849-498e-8175-a1a045f7ee1a"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety evaluation of NORTHERA is based on two placebo-controlled studies 1 to 2 weeks in duration (Studies 301 and 302), one 8-week placebo-controlled study (Study 306), and two long-term, open-label extension studies (Studies 303 and 304).Â  In the placebo-controlled studies, a total of 485 patients with Parkinson's disease, multiple system <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, pure autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span> were randomized and treated, 245 with NORTHERA and 240 with placebo <span class="Italics">[see Clinical Studies (<a href="#LINK_9b3623f8-bafb-4b71-8261-9c64d371d2ab">14</a>)]</span>.Â  </p>
<p><span class="Bold"><span class="Italics">Placebo-Controlled </span></span><span class="Bold"><span class="Italics">Experience</span></span></p>
<p>The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%Â  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.Â  The most common adverse reactions leading to discontinuation from NORTHERA were <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<table>
<caption><span>Table 1. Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3">Â Â <br>Â Â <br>Â Â Â Â Â Â  </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Â Â <span class="Bold">Study 301 and Study 302</span><br><span class="Bold">(1 to 2 Weeks Randomized Treatment)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Â Â <span class="Bold">Study 306</span><br><span class="Bold">(8 to 10 Weeks Randomized Treatment)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â Â <span class="Bold">Placebo</span><br><span class="Bold">(N=132)</span><br>Â Â <span class="Bold">n (%)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â Â <span class="Bold">NORTHERA</span><br><span class="Bold">(N=131)</span><br>Â Â <span class="Bold">n (%)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â Â <span class="Bold">Placebo</span><br><span class="Bold">(N=108)</span><br>Â Â <span class="Bold">n (%)</span>
</td>
<td class="Lrule Rrule Toprule" align="center">Â Â <span class="Bold">NORTHERA</span><br><span class="Bold">(N=114)</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center">Â Â <span class="Bold">n (%)</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  4 (3.0) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  8 (6.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  8 (7.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  15 (13.2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  2 (1.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  5 (3.8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  5 (4.6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  11 (9.6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  2 (1.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  2 (1.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  5 (4.6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  10 (8.8) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â Â  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  0 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  2 (1.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  1 (0.9) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  8 (7.0) </td>
</tr>
</tbody>
</table>
<p>Note: n=number of patients.Â  Table displays adverse reactions that were reported in greater than 5% of patients in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group.</p>
<p><span class="Bold"><span class="Italics">Long-Term, Open-Label Trials with NORTHERA<br></span></span>In the long-term, open-label extension studies, a total of 422 patients, mean age 65 years, were treated with NORTHERA for a mean total exposure of approximately one year. The commonly reported adverse events were <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> (24%), <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (15%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (13%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (10%). </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_717da11a-94e9-4ec7-9831-551d655b62db"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_01f70c16-ea6e-47b0-b951-1efce4c02b6e"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs that Increase Blood Pressure</h2>
<p class="First">Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6fcf6183-6379-4a4b-b1c7-9bba776cdaeb"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Parkinson's Medications</h2>
<p class="First">Dopa-decarboxylase inhibitors may require dose adjustments for NORTHERA.Â  </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_a0177d7d-ac7e-4419-8d54-4b121ca365b5"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_982b2ff5-21e5-43ef-8231-a172554d29e1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category C<br></span></span>There are no adequate and well-controlled trials in pregnant women.Â  </p>
<p>Following consecutive oral administration at doses of 60, 200, and 600 mg/kg/day to pregnant Sprague Dawley rats, increased incidences of lower body weight and occurrence of undulant rib were noted in fetuses, but they were slight and spontaneously reversed after birth. Based on dose per unit body surface area, these three doses correspond to approximately 0.3, 1, and 3 times, respectively, the maximum recommended total daily dose of 1,800 mg in a 60 kg patient.Â  Shortening of the gestation period was observed in rats at 600 mg/kg/day. Low incidences of renal lesions (<span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, indentations, or renal pelvic dilation) were observed on the surface of the kidneys of female rats treated with droxidopa during the period of fetal organogenesis. No other potentially teratogenic effects have been observed in rats or rabbits.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_9cd96db8-bd87-4944-b9da-f35534352f52"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Choose nursing or NORTHERA. In rats, droxidopa is excreted in breast milk, and when the drug was administered to the nursing dams during the period of lactation, reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and reduced survival were observed in the offspring.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ecd41953-cd15-44d6-ba7d-b642a4a0aa67"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of NORTHERA in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_da14ee16-9421-4a71-b7e4-dd0bee124162"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">A total of 197 patients with symptomatic NOH aged 75 years or above were included in the NORTHERA clinical program.Â  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e55a9213-2aa2-4b7e-aa79-ca3e8d09b210"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">NORTHERA and its metabolites are primarily cleared renally.Â  Patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR greater than 30 mL/min) were included in clinical trials and did not have a higher frequency of adverse reactions.Â  Clinical experience with NORTHERA in patients with severe renal function impairment (GFR less than 30 mL/min) is limited.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_6f8e599e-ac2b-445a-8fa9-8be86e3d1eaf"></a><a name="section-9"></a><p></p>
<h1>
10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3a6c9e96-eb48-41ff-83b7-0bfee914c700"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Symptoms</h2>
<p class="First">There was one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> reported during post-marketing surveillance in Japan.Â  The patient ingested 7,700 mg of NORTHERA and experienced a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> that resolved promptly with treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d8407206-b178-4922-aef6-285d67ee3eb9"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Treatment</h2>
<p class="First">There is no known antidote for NORTHERA overdosage.Â  In case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> that may result in an excessively high blood pressure, discontinue NORTHERA and treat with appropriate symptomatic and supportive therapy.Â  Counsel patients to remain in a standing or seated position until their blood pressure drops below an acceptable limit. </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_d9be1f9e-cadd-4fe7-b2c2-d5fe10bb431a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration.Â  Chemically, droxidopa is (â€“)-threo-3-(3,4-Dihydroxyphenyl)-L-serine.Â  It has the following structural formula:<br><img alt="northera-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-1.jpg"></p>
<p>Droxidopa is an odorless, tasteless, white to off-white crystals or crystalline powder.Â  It is slightly soluble in water, and practically insoluble in methanol, glacial acetic acid, ethanol, acetone, ether, and chloroform.Â  It is soluble in dilute hydrochloric acid.Â  It has a molecular weight of 213.19 and a molecular formula of C<span class="Sub">9</span>H<span class="Sub">11</span>NO<span class="Sub">5</span>. </p>
<p>NORTHERA capsules also contain the following inactive ingredients: mannitol, corn starch, and magnesium stearate.Â  The capsule shell is printed with black ink.Â  The black inks contain shellac glaze, ethanol, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol, and ammonium hydroxide.Â  The capsule shell contains the following inactive ingredients: 100 mg â€“Â­ gelatin, titanium dioxide, FD&amp;C Blue No. 2, black and red iron oxide; 200 mg â€“ gelatin, titanium dioxide, FD&amp;C Blue No. 2, black and yellow iron oxide; 300 mg â€“ gelatin, titanium dioxide, FD&amp;C Blue No. 1, FD&amp;C Yellow No. 5 (tartrazine), and FD&amp;C Red No. 40. NORTHERA capsules differ in size and color by strength <span class="Italics">[see Dosage Forms and Strengths (<a href="#LINK_b7e8ffed-3655-4f27-9e97-b56b0ff05651">3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_a0902af0-c105-4853-ae11-24f547409c43"></a><a name="section-11"></a><p></p>
<h1>
12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_0c459c94-5df5-46a9-9883-cc371bd4a08c"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The exact mechanism of action of NORTHERA in the treatment of neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> is unknown. NORTHERA is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopaÂ­-decarboxylase, which is extensively distributed throughout the body. NORTHERA is believed to exert its pharmacological effects through norepinephrine and not through the parent molecule or other metabolites. Norepinephrine increases blood pressure by inducing peripheral arterial and venous <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>.Â  NORTHERA in humans induces small and transient rises in plasma norepinephrine. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_5a37b5ae-750e-4932-af8e-b9748e12cd57"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Peak droxidopa plasma concentrations are associated with increases in systolic and diastolic blood pressures.Â  Droxidopa has no clinically significant effect on standing or supine heart rates in patients with autonomic failure.</p>
<p><span class="Italics"><span class="Bold">Cardiac Electrophysiology</span></span><span class="Underline"><br></span>No prolongation of the QTc interval was observed with NORTHERA at single oral doses up to 2,000 mg, as shown in a dedicated thorough QT study.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_18c0a7cc-b6f7-4560-8e85-a6e00bc83f9a"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption<br></span></span>Peak plasma concentrations (C<span class="Sub">max</span>) of droxidopa were reached by 1 to 4 hours post-dose (mean of approximately 2 hours) in healthy volunteers. Â High-fat meals have a moderate impact on droxidopa exposure with C<span class="Sub">max</span> and area under the plasma concentration-time curve (AUC) decreasing by 35% and 20%, respectively. The C<span class="Sub">max</span> was delayed by approximately 2 hours with a high-fat meal.Â Â Â </p>
<p><span class="Bold"><span class="Italics">Distribution<br></span></span>Pre-clinical studies suggest that droxidopa can cross the blood brain barrier. Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL. Â The estimated apparent volume of distribution of droxidopa is about 200 L in humans.</p>
<p><span class="Bold"><span class="Italics">Metabolism<br></span></span>The metabolism of droxidopa is mediated by catecholamine pathway and not through the cytochrome P450 system. Droxidopa is initially converted to methoxylated dihydroxyphenylserine (3-OM-DOPS), a major metabolite, by catechol-O-methyltransferase (COMT), to norepinephrine by DOPA decarboxylase (DDC), or to protocatechualdehyde by DOPS aldolase. After oral dosing in humans, plasma norepinephrine levels peak within 3 to 4 hours but are generally very low (less than 1 ng/mL) and variable with no consistent relationship with dose. The contribution of the metabolites of droxidopa other than norepinephrine to its pharmacological effects is not well understood. </p>
<p><span class="Bold"><span class="Italics">Excretion<br></span></span>The mean elimination half-life of droxidopa is approximately 2.5 hours in humans. The major route of elimination of droxidopa and its metabolites is via the kidneys in both animals and in humans. Studies in animals showed that ~75% of the radiolabeled dose was excreted in urine within 24 hours of oral dosing.Â Â </p>
<p><span class="Bold"><span class="Italics">Special Populations<br></span></span>There are no clinically relevant effects of age, body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index, or sex on the pharmacokinetics of droxidopa. A population pharmacokinetic analysis suggests that hepatic function, assessed by <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), alkaline phosphatase, and total bilirubin, did not influence the exposure to droxidopa. The controlled clinical trials included patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.Â  No dose adjustments are required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.Â  </p>
<p><span class="Bold"><span class="Italics">Drug Interactions<br></span></span>No dedicated drug-drug interaction studies were performed for droxidopa. Patients in the Phase 3 trials with NORTHERA received concomitant levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and other medications used to treat Parkinsonâ€™s disease.Â  Carbidopa, a peripheral dopa-decarboxylase inhibitor, could prevent the conversion of NORTHERA to norepinephrine outside of the central nervous system (CNS).Â  Patients taking NORTHERA with L-DOPA/dopa-decarboxylase inhibitor combination drugs had decreased clearance of NORTHERA, an increase in exposure (AUC) to droxidopa of approximately 100%, and an increase in exposure to 3-OM-DOPS of approximately 50%.Â  However, in clinical trials, it was found that the decreased clearance was not associated with a significant need for a different treatment dose or increases in associated adverse events.Â  Dopamine agonists, amantadine derivatives, and MAO-B inhibitors do not appear to affect NORTHERA clearance, and no dose adjustments are required.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_44f926e1-65b2-4b3b-a821-7ae3d28b145f"></a><a name="section-12"></a><p></p>
<h1>
13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_13f84147-30c1-4933-ba76-6b4b9ad8e3ce"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies have been conducted at dosages up to 1,000 mg/kg/day in mice and up to 100 mg/kg/day in rats with no indication of carcinogenic effects. Based on dose per unit body surface area, these two doses correspond to approximately 3 and 0.5 times, respectively, the maximum recommended total daily dose of 1,800 mg in a 60 kg patient. Droxidopa was clastogenic in Chinese hamster ovary cells (chromosome aberration assay), but was not mutagenic in bacteria (Ames assay), and was not clastogenic in a mouse micronucleus assay. </p>
<p>Studies in rats show that droxidopa has no effect on fertility.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_4c813f3e-051b-4f3c-9a6f-bf75197528b0"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and Pharmacology</h2>
<p class="First">Rats and mice treated for 52 and 80 weeks, respectively, at doses similar to human doses (100 to 300 mg/kg/day for rats and 300 to 1,000 mg/kg/day for mice) had increased incidences of renal and cardiac lesions (rats and mice) and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (rats only). No signs of toxicity were observed in monkeys or dogs given droxidopa for 13 weeks at doses 32 times (3,000 mg/kg/day) and 37 times (2,000 mg/kg/day), respectively, the maximum recommended total daily dose of 1,800 mg in a 60 kg patient, when based on body surface area. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_9b3623f8-bafb-4b71-8261-9c64d371d2ab"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ea54a2b2-5228-4025-83aa-131a71ca309d"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Studies in Neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Clinical studies (described below) examined the efficacy of NORTHERA in the short-term (1 to 2 weeks) and over longer-term periods (8 weeks; 3 months).Â  Studies 301 and 306B showed a treatment effect of NORTHERA at Week 1, but none of the studies demonstrated continued efficacy beyond 2 weeks of treatment.</p>
<p>Study 306B was a multi-center, double-blind, randomized, placebo-controlled, parallel-group study in patients with symptomatic NOH and Parkinsonâ€™s disease.Â  Patients entering the study were required to have a decrease of at least 20 mm Hg or 10 mm Hg, respectively, in systolic or diastolic blood pressure, within 3 minutes after standing, as well as symptoms associated with neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. The study had an initial dose titration period that lasted up to 2 weeks in which patients received placebo or 100 to 600 mg of NORTHERA three times daily, followed by an 8-week treatment period.Â Â  </p>
<p>Efficacy was measured using the OHSA Item #1 score (â€œdizziness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, and feeling like you might black outâ€?) at Week 1, in patients who had completed titration and 1 week of maintenance therapy. </p>
<p>A total of 171 patients were enrolled, and 147 patients were included in the efficacy analysis.Â  The mean age was 72 years, and patients were mostly Caucasian.Â  During the study, 94% of placebo-treated patients and 88% on NORTHERA were taking dopa-decarboxylase inhibitors; 17% of placebo-treated patients and 26% on NORTHERA were taking fludrocortisone. There were more premature discontinuations in the NORTHERA group (28%) than in the placebo group (20%). </p>
<p>In both groups, the mean baseline <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> score was 5.1 on an 11-point scale. Â At Week 1, patients showed a statistically significant mean 0.9-unit decrease in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> with NORTHERA versus placebo (<span class="Italics">P</span>=0.028), but the effect did not persist beyond Week 1. The data at all time points are shown in Figure 1. Â </p>
<p>Patients receiving NORTHERA also had a greater increase, compared to placebo, in the Week 1 lowest standing systolic blood pressure within 3 minutes after standing (5.6 mm Hg; <span class="Italics">P</span>=0.032).</p>
<p><span class="Bold">Figure 1. Mean Change in OHSA Item 1 Score by Week in Study 306B</span></p>
<div class="Figure"><img alt="Figure 1. Mean Change in OHSA Item 1 score by week in Study 306B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-2.jpg"></div>
<p>Note: The graph is based on observed data only. The error bars are the 95% confidence interval of the mean change from baseline in OHSA Item 1 scores.</p>
<p><span class="Bold">Figure 2. Distribution of Patients by Change in OHSA Item 1, Baseline to Week 1, in Study 306B</span></p>
<p>Figure 2 shows the distribution of changes from Baseline to Week 1 in the OHSA Item #1 score.Â  Overall the figure shows that patients treated with NORTHERA improved more than those treated with placebo.Â  </p>
<div class="Figure"><img alt="Figure 2. Distribution of Patients by Change in OHSA Item 1, Baseline to Week 1, in Study 306B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-3.jpg"></div>
<p>Study 301 was a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study in patients with symptomatic neurogenic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.Â  The study included an initial open-label dose titration period, a 7-day washout period, and a randomized double-blind 7-day treatment period.Â  To be eligible for enrollment, patients were required to have a decrease in systolic or diastolic blood pressure of at least 20 or 10 mm Hg, respectively, within 3 minutes after standing.Â  The study was enriched, such that only patients who had been identified as â€˜respondersâ€™ during the titration period were randomized to NORTHERA or placebo.Â  To be considered a responder, a patient had to demonstrate improvement on the OHSA Item #1 score by at least 1 point, as well as an increase in systolic blood pressure of at least 10 mm Hg post-standing, during the open-label dose titration period.Â  Patients who dropped out during the titration period because of side effects or other reasons were also not included in the double-blind portion of the study. </p>
<p>Patients had a primary diagnosis of Parkinsonâ€™s disease (n=60), pure autonomic failure (n=36), or multiple system <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> (n=26).Â  The mean age was 60 years, and most were Caucasian. 45% of patients were taking dopa-decarboxylase inhibitors, and 29% were taking fludrocortisone.Â  </p>
<p>Efficacy was measured using the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> Questionnaire (OHQ), a patient-reported outcome that measures symptoms of NOH and their impact on the patientâ€™s ability to perform daily activities that require standing and walking.Â  The OHQ includes OHSA Item #1 as one of several components. A statistically significant treatment effect was not demonstrated on OHQ (treatment effect of 0.4 unit, <span class="Italics">P</span>=0.19). </p>
<p>The mean baseline <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> score on OHSA Item #1 (â€œdizziness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, and feeling like you might black outâ€?) was 5.2 units on an 11-point scale. Â At Week 1 of treatment, patients showed a mean 0.7-unit decrease in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> with NORTHERA versus placebo (<span class="Italics">P</span>=0.06). </p>
<p>Study 302 (n=101) was a placebo-controlled, 2-week randomized withdrawal study of NORTHERA in patients with symptomatic NOH.Â  Study 303 (n=75) was an extension of Studies 301 and 302, where patients received their titrated dose of NORTHERA for 3 months and then entered a 2-week randomized withdrawal phase.Â  Neither study showed a statistically significant difference between treatment arms on its primary endpoint.Â  Considering these data, the effectiveness of NORTHERA beyond 2 weeks is uncertain, and patients should be evaluated periodically to determine whether NORTHERA is continuing to provide a benefit.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_64e3c920-7da2-41d1-afa8-bc7135cc80e3"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_4cc5ef73-92d9-4b30-aff1-9378b572c2ca"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">NORTHERA capsules are supplied in the following dosage strengths:</p>
<p>100 mg:Â  Hard gelatin, size 3 capsule, with an opaque light blue cap and an opaque white body, printed with â€œNortheraâ€? on body and â€œ100â€? on cap, filled with a white to light brown powder.</p>
<p>200 mg: Â Hard gelatin, size 2 capsule, with an opaque light yellow cap and an opaque white body, printed with â€œNortheraâ€? on body and â€œ200â€? on cap, filled with a white to light brown powder.</p>
<p>300 mg: Â Hard gelatin, size 1 capsule, with an opaque light green cap and an opaque white body, printed with â€œNortheraâ€? on body and â€œ300â€? on cap, filled with a white to light brown powder.</p>
<p>100 mg 90-count bottle (NDC code# 67386-820-19)</p>
<p>200 mg 90-count bottle (NDC code# 67386-821-19)</p>
<p>300 mg 90-count bottle (NDC code# 67386-822-19)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_8fd49e8c-5150-4b08-af6f-1970f5c80611"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">NORTHERA capsules should be stored at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted to 15Â°C to 30Â°C (59Â°F to 86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_aab2fccb-0f79-40ba-8ae3-07eb9337ab73"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">Elevations in Blood Pressure<br></span>Counsel patients that NORTHERA causes elevations in blood pressure and increases the risk of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, which could lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Instruct patients to rest and sleep in an upper-body elevated position and monitor blood pressure.Â  Instruct patients how to manage observed blood pressure elevations.Â  To reduce the risk of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, in addition to raising the upper body, the late afternoon dose of NORTHERA should be taken at least three hours before bedtime.</p>
<p><span class="Bold">Concomitant Treatments<br></span>Counsel patients about the concomitant use of drugs to treat other conditions that may have an additive effect with NORTHERA <span class="Italics">[see Drug Interactions (<a href="#LINK_717da11a-94e9-4ec7-9831-551d655b62db">7</a>)].</span></p>
<p><span class="Bold">Pregnancy<br></span>Counsel patients to consult a physician if they are nursing, pregnant, or planning to become pregnant while taking NORTHERA.</p>
<p><span class="Bold">Food<br></span>Patients should take NORTHERA the same way each time, either with food or without food.</p>
<p><span class="Bold">Missed Dose<br></span>If a dose is missed, patients should take the next dose at the regularly scheduled time and should not double the dose.</p>
<p>Manufactured for: <br>Lundbeck<br>Deerfield, IL 60015, U.S.A.<br><br>[Lundbeck Logo]</p>
<p>TM of Lundbeck NA Ltd.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_d8cd3d72-939f-4296-be51-e52a4d6d5c6a"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">NDC 67386-820-19<br>90 Capsules<br>Northera<span class="Sup">â„¢</span><br>(droxidopa) capsules<br>100 mg<br>Rx Only </p>
<div class="Figure"><img alt="NDC 67386-820-19 90 Capsules Northera (droxidopa) capsules 100 mg Rx Only" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_e6282910-e6a5-425f-95f3-2b1b18cdad90"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">NDC 67386-821-19<br>90 Capsules<br>Northera<span class="Sup">â„¢</span><br>(droxidopa) capsules<br>200 mg<br>Rx Only</p>
<div class="Figure"><img alt="NDC 67386-821-19 90 Capsules Northera (droxidopa) capsules 200 mg Rx Only" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-5.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f56ce2ce-921c-4f9d-be61-8d986532caf7"></a><a name="section-18"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">NDC 67386-822-19<br>90 Capsules<br>Northera<span class="Sup">â„¢</span><br>(droxidopa) capsules<br>300 mg<br>Rx Only</p>
<div class="Figure"><img alt="NDC 67386-822-19 90 Capsules Northera (droxidopa) capsules 300 mg Rx Only" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&amp;name=northera-6.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NORTHERAÂ 		
					</strong><br><span class="contentTableReg">droxidopa capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67386-820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DROXIDOPA</strong> (DROXIDOPA) </td>
<td class="formItem">DROXIDOPA</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (light blue cap) ,Â WHITE (opaque white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Northera;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67386-820-19</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203202</td>
<td class="formItem">09/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NORTHERAÂ 		
					</strong><br><span class="contentTableReg">droxidopa capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67386-821</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DROXIDOPA</strong> (DROXIDOPA) </td>
<td class="formItem">DROXIDOPA</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (opaque light yellow cap) ,Â WHITE (opaque white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Northera;200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67386-821-19</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203202</td>
<td class="formItem">09/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NORTHERAÂ 		
					</strong><br><span class="contentTableReg">droxidopa capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67386-822</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DROXIDOPA</strong> (DROXIDOPA) </td>
<td class="formItem">DROXIDOPA</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 5</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (opaque light green cap) ,Â WHITE (opaque white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Northera;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67386-822-19</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203202</td>
<td class="formItem">09/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Lundbeck LLC
							(018343595)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Inc.</td>
<td class="formItem"></td>
<td class="formItem">205475333</td>
<td class="formItem">MANUFACTURE(67386-820, 67386-821, 67386-822)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>32c0f213-4479-4a01-b6fe-e58a104735c7</div>
<div>Set id: 2179f02c-48d7-48eb-8007-5ae43d8d16bc</div>
<div>Version: 8</div>
<div>Effective Time: 20140801</div>
</div>
</div>Â <div class="DistributorName">Lundbeck LLC</div></p>
</body></html>
